

# The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY**  
**MAY 19<sup>TH</sup>**

8:00 – 8:30		
Registration and Joint Breakfast, attach Posters		
8:30 – 9:00		
Opening of the Conference – <i>Andreas Köpke, bioExpert</i>		
Mainz, the most dynamic life science and biotechnology hub in Germany! – <i>Jan Uphoff, biomindz</i>		
9:00 – 9:30		
New modes of action for targeting neurodegenerative diseases: restoring the septin cytoskeleton <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
PANEL 09:30 – 10:30		
Protein Aggregation in Neurodegeneration	Biomolecular condensates in neurodegeneration	<b>Markus Zweckstetter</b> DZNE Göttingen, Germany
	Importins as Regulators of Phase Transitions – From Mechanisms to Novel Therapeutics	<b>Miriam Linsenmeier</b> University of Pennsylvania, USA
Aβ Antibody Comparison	Comparative treatment of 5xFAD mice applying mono- clonal antibodies directed against pGlu3-, isoAsp7 and Nitro-Tyr10 Abeta	<b>Stephan Schilling</b> Fraunhofer-Institute for Cell Therapy and Immunology, Germany
Panel Q&A of Session Speakers <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
10:30 – 11:30		
Coffee Break, Exhibition & Poster Viewing		
PANEL 11:30 – 12:30		
Tau Antibodies as Novel Therapeutic Option	Clearance of intracellular tau protein pathology through novel immunotherapy approaches	<b>Rakez Kayed</b> UMTB, USA
In vivo Disease Models	Preclinical strategies for assessment of therapeutics targeting early stages of proteinopathies	<b>Joseph Arauja</b> Transphormation, Canada
	Development and characterization of a dual (amyloid and tau) pathology mouse model for Alzheimer's disease	<b>Julian Sefrin</b> AbbVie Deutschland, Germany
Panel Q&A of Session Speakers <i>Chair: Gerard Griffioen, reMYND, Belgium</i>		
12:30		
Lunch		

# The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY**  
**MAY 19<sup>TH</sup>**

13:30		
Protein degradation mechanisms as novel therapeutic approaches for neurodegenerative diseases <i>Chair: Christiane Volbracht, H. Lundbeck, Denmark</i>		
PANEL 14:00 – 15:00		
New Treatment Modality	Induced proximity probes for therapeutic concepts in neurodegenerative diseases	Nur Kocaturk University of Dundee, UK
Proteomics Services	Characterizing target degrader compounds on the protein level in cell culture and tissue samples	Hannes Hahne OmicScouts, Germany
New Treatment Modality	BioPROTAC degradation of misfolded SOD1 as a potential therapeutic for amyotrophic lateral sclerosis (ALS)	Christen Chisholm University of Wollongong, Australia
Panel Q&A of Session Speakers <i>Chair: Christiane Volbracht, H. Lundbeck, Denmark</i>		
15:00 – 16:00		
Coffee Break, Exhibition & Poster Session (All Presenters will be at their posters for discussion. Please vote for the best poster!) Time for One on One Meetings		
PANEL 16:00 – 17:00		
New Treatment Modality	Reliable intrabodies for neurodegenerative disease	Gareth Wright University of Essex, UK
In vivo Disease Models	The combination of genetic and induced risk factors in animal models of aging	Lone Bruhn Madsen Scantox, Sweden
New Treatment Modality	PRI-101, an optimized oligomer-disassembling compound as potential drug candidate for synucleinopathies	Antje Willuweit Priavoid, Germany
Panel Q&A of Session Speakers <i>Chair: Christiane Volbracht, H. Lundbeck, Denmark</i>		
17:00		
Reception in the Foyer		
18:30 – 22:00		
Dinner We will have a seated dinner, accompanied by fitting local wines! Depending on the weather, we will be on the hotel terrace, or in an adjacent room.		
END OF THE FIRST DAY		

# The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 20<sup>TH</sup>**

8:00		
Joint Breakfast, Exhibition & Poster Viewing (Please vote for the best poster!)		
8:30		
Therapeutic vaccines and antibodies for AD, PD and ALS <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i>		
PANEL 9:00 – 10:00		
Finding new AD Targets	Harnessing viruses for drug discovery and target identification in neurodegenerative diseases	<b>Carsten Korth</b> Heinrich Heine University, Germany
Diagnosis of Prion Disease	Defining the onset of prion infection and neurodegeneration in healthy individuals at risk of prion disease	<b>Tzehow Mok</b> Institute of Prion Diseases and MRC Prion Unit, UK
New Treatment Modality and Route of Administration	Nose-to-brain small RNA delivery to treat Parkinson's disease	<b>Franziska Richter Assencio</b> University of Hannover, Germany
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i>		
10:00 – 11:00		
Coffee Break, Exhibition & Poster Session All Presenters will be at their posters for discussion. (Final chance to rate the best poster!) Time for One on One Meetings		
PANEL 11:00 – 12:00		
PD Diagnostics	Diagnosis of Parkinson's disease from peripheral tissues	<b>Walter J. Schulz-Schaeffer</b> University of the Saarland, Germany
AD Diagnostic	Alzheimer's diagnosis based on fluid biomarkers only: Future or fiction?	<b>Oliver Peters</b> Charité, Germany
Repurposed Therapeutic	Levodopa use in Alzheimer's disease and spinocerebellar ataxia type 3: molecular, preclinical and clinical evidence	<b>Pedro Martins</b> Instituto de Biologia Molecular e Celular – IBMC, Portugal
Panel Q&A of Session Speakers <i>Chair: Neil Cashman, ProMIS Neurosciences, Canada</i>		
12:00		
Lunch		

# The Neuro4D Conference 2025

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 20<sup>TH</sup>**

13:00		
Implementation of new Amyloid antibody treatments in Germany – guidance and challenges Chair: Lutz Frölich, University of Heidelberg, Germany		
PANEL 13:30 – 14:30		
AD Clinical Development	PRI-002 for the treatment of Alzheimer’s disease	Dieter Willbold Research Centre Jülich, Germany
	Eisai clinical trials: Clarity AD & AHEAD 3-45	Oliver Peters Charité, Germany
Panel Q&A of Session Speakers Chair: Lutz Frölich, University of Heidelberg, Germany		
14:30		
Coffee Break & Final Poster Session		
15:00		
Pannel Discussion: Current therapeutic options and future implications		
<ul style="list-style-type: none"><li>• When to best start therapy in Alzheimers disease with the newly registered antibodies? How much patient benefit can be achieved?</li><li>• What achievements do we need from the next successful AD therapeutic to make a meaningful difference over current standard of treatment?</li><li>• Which role do symptomatic therapies play to keep patients autonomous?</li></ul>		
Pannel Participants:		
Lutz Frölich	University of Heidelberg, Germany	
Oliver Peters	Charité, Germany	
Gerard Griffioen	reMYND, Belgium	
Neil Cashman	ProMIS Neurosciences, Canada	
Moderator: Andreas Köpke		
16:15		
Price for the Best Poster ‘Best Results towards Treatment of Neurodegenerative Diseases’ presented at the International Neuro4D Conference 2025		
16:25		
Summary and Wrap-Up of the Conference		
16:30		
END OF THE CONFERENCE AND DEPARTURE		